<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo270075" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39925770</article-id><article-id pub-id-type="pmc">PMC11803297</article-id>
<article-id pub-id-type="doi">10.1002/deo2.70075</article-id><article-id pub-id-type="publisher-id">DEO270075</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Side&#x02010;by&#x02010;side versus stent&#x02010;in&#x02010;stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction</article-title><alt-title alt-title-type="left-running-head">IMAMURA <sc>et&#x000a0;al</sc>.</alt-title></title-group><contrib-group><contrib id="deo270075-cr-0001" contrib-type="author"><name><surname>Imamura</surname><given-names>Shunsuke</given-names></name><xref rid="deo270075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270075-cr-0002" contrib-type="author"><name><surname>Watanabe</surname><given-names>Kazuo</given-names></name><xref rid="deo270075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270075-cr-0003" contrib-type="author"><name><surname>Inoue</surname><given-names>Kanae</given-names></name><xref rid="deo270075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270075-cr-0004" contrib-type="author"><name><surname>Taira</surname><given-names>Tomonao</given-names></name><xref rid="deo270075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270075-cr-0005" contrib-type="author"><name><surname>Shibuki</surname><given-names>Taro</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7302-7691</contrib-id><xref rid="deo270075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270075-cr-0006" contrib-type="author"><name><surname>Satake</surname><given-names>Tomoyuki</given-names></name><xref rid="deo270075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270075-cr-0007" contrib-type="author"><name><surname>Yamaguchi</surname><given-names>Shota</given-names></name><xref rid="deo270075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270075-cr-0008" contrib-type="author"><name><surname>Sasaki</surname><given-names>Mitsuhito</given-names></name><xref rid="deo270075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270075-cr-0009" contrib-type="author"><name><surname>Imaoka</surname><given-names>Hiroshi</given-names></name><xref rid="deo270075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270075-cr-0010" contrib-type="author"><name><surname>Mitsunaga</surname><given-names>Shuichi</given-names></name><xref rid="deo270075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270075-cr-0011" contrib-type="author" corresp="yes"><name><surname>Ikeda</surname><given-names>Masafumi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4050-2086</contrib-id><xref rid="deo270075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>masikeda@east.ncc.go.jp</email></address></contrib></contrib-group><aff id="deo270075-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Hepatobiliary and Pancreatic Oncology</named-content>
<institution>National Cancer Center Hospital East</institution>
<city>Chiba</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Masafumi Ikeda, Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6&#x02010;5&#x02010;1, Kashiwanoha, Kashiwa, Chiba 277&#x02010;8577, Japan.<break/> Email: <email>masikeda@east.ncc.go.jp</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="23">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e70075</elocation-id><history>
<date date-type="rev-recd"><day>21</day><month>1</month><year>2025</year></date>
<date date-type="received"><day>09</day><month>11</month><year>2024</year></date>
<date date-type="accepted"><day>27</day><month>1</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e70075.pdf"/><abstract><title>Abstract</title><sec id="deo270075-sec-0010"><title>Objectives</title><p>With the improved prognosis of patients with biliary tract cancer (BTC) owing to advances in chemotherapy, long&#x02010;term stent patency has become an important goal in patients undergoing biliary stent placement. We compared the duration of stent patency between unresectable BTC patients undergoing multi&#x02010;stenting for malignant hilar biliary obstruction by the side&#x02010;by&#x02010;side (SBS) and stent&#x02010;in&#x02010;stent (SIS) techniques during systemic chemotherapy.</p></sec><sec id="deo270075-sec-0020"><title>Methods</title><p>We retrospectively evaluated the data of 62 unresectable BTC patients who underwent multi&#x02010;stenting before the first or second cycle of first&#x02010;line chemotherapy. Stent deployment was performed by the SBS technique in 40 patients (SBS group) and by the SIS technique in 22 patients (SIS group).</p></sec><sec id="deo270075-sec-0030"><title>Results</title><p>The median time&#x02010;to&#x02010;recurrent biliary obstruction was 147 days in the SBS group and 252 days in the SIS (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.029), being longer in the SIS group. The rates of development of early adverse events were 28% and 9% (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.09) and the rates of development of late adverse events were 26% and 14% in the SBS and SIS groups (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.27). The median overall survival was 480 days in the SBS group and 563 days in the SIS group (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.92).</p></sec><sec id="deo270075-sec-0040"><title>Conclusion</title><p>The duration of stent patency was shorter in the SBS group than in the SIS group; thus, the SIS technique is preferable to the SBS technique for biliary stent deployment in unresectable BTC patients during systemic chemotherapy.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo270075-kwd-0001">biliary tract cancer</kwd><kwd id="deo270075-kwd-0002">chemotherapy</kwd><kwd id="deo270075-kwd-0003">malignant hilar biliary obstruction</kwd><kwd id="deo270075-kwd-0004">side&#x02010;by&#x02010;side</kwd><kwd id="deo270075-kwd-0005">stent&#x02010;in&#x02010;stent</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>None</funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="5"/><page-count count="8"/><word-count count="4549"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="deo270075-sec-0050"><title>INTRODUCTION</title><p>Multiple or bilateral metallic stenting is widely used for liver drainage and palliation in malignant biliary obstruction (MBO).<xref rid="deo270075-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="deo270075-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="deo270075-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="deo270075-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> The side&#x02010;by&#x02010;side (SBS) and stent&#x02010;in&#x02010;stent (SIS) techniques are the main methods used for multi&#x02010;stenting in patients with hilar MBO.<xref rid="deo270075-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="deo270075-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> While the SBS technique is relatively easy for stent placement and re&#x02010;intervention, it is prone to bile duct overexpansion. The SIS technique allows more natural placement with less overexpansion, although breakage through the stent mesh could be a challenge.<xref rid="deo270075-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> There are also reports of no significant difference in the duration of patency between SBS and SIS,<xref rid="deo270075-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="deo270075-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> reports of longer patency in SBS,<xref rid="deo270075-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> and reports of longer patency in SIS,<xref rid="deo270075-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> all of which are inconclusive. Choosing between SBS and SIS for hilar MBO remains controversial due to varied patient backgrounds, including cancer types and chemotherapy regimens. Therefore, we compared SBS and SIS stent patency during chemotherapy for unresectable biliary tract cancer (BTC). Since a longer duration of uninterrupted chemotherapy can improve a patient's prognosis, we also examined the effect of stenting on the duration of chemotherapy and number of chemotherapy interruptions needed in the patients.</p></sec><sec id="deo270075-sec-0060"><title>METHODS</title><sec id="deo270075-sec-0070"><title>Study Design</title><p>This was a single&#x02010;institutional retrospective study. The Institutional Review Board of the National Cancer Center (#2020&#x02010;209) approved the study, which adhered to the Declaration of Helsinki. The ethics committee of our hospital waived the need to obtain consent from the patients since this work involved retrospective use of anonymized patient data.</p></sec><sec id="deo270075-sec-0080"><title>Patients</title><p>Between January 2016 and August 2021, 896 unresectable BTC patients were admitted to our hospital. The patient inclusion criteria were as follows: (1) patients with histopathologically diagnosed BTC who were receiving systemic chemotherapy; (2) patients who underwent multi&#x02010;metallic stenting of the hilar bile duct; (3) patients in whom stenting was performed prior to induction or second cycle of first&#x02010;line chemotherapy. To assess the effect of stent patency and chemotherapy, we extracted patients who had undergone stent placement before the first or second cycle of first&#x02010;line chemotherapy. The exclusion criteria were as follows: (1) plastic stent placement; (2) no stent placement; (3) surgically altered anatomy; (4) distal bile duct stent placement; (5) unilateral stent placement; (6) no chemotherapy planned; and (7) stent inserted after the second cycle of first&#x02010;line chemotherapy. The SBS technique was mainly used in 2016&#x02013;2019 and the SIS technique in 2020&#x02013;2021.</p></sec><sec id="deo270075-sec-0090"><title>Procedures</title><p>First, two guidewires were inserted into the bile ducts. In the SBS method for stent deployment, the first self&#x02010;expanding metallic stent (SEMS) was placed on one side over the guidewire, followed by the placement of the second SEMS on the other side. Both the SEMSs were oriented in parallel in the common bile duct (Figure&#x000a0;<xref rid="deo270075-fig-0001" ref-type="fig">1a</xref>). For SIS deployment, after the first SEMS had been inserted into one side over the guidewire, insertion of the guidewire employed for placement of the first SEMS into the other side via the central open mesh of the first SEMS was performed using, as a landmark, the guidewire that had been inserted in the other side before insertion of the first SEMS. The two SEMS overlapped in the common bile duct (Figure&#x000a0;<xref rid="deo270075-fig-0001" ref-type="fig">1b</xref>). Uncovered braided SEMSs with diameters of 8 or 10&#x000a0;mm and lengths sufficient to cover the stenotic area were selected. Endoscopic sphincterotomy was performed in all the patients who underwent stent placement. Re&#x02010;intervention typically involved placing an inner plastic stent after balloon extraction of ductal debris. Endoscopists with less than 5 years of experience in endoscopy were defined as trainees, and those with experience of 5 years or over were defined as experts.</p><fig position="float" fig-type="FIGURE" id="deo270075-fig-0001"><label>FIGURE 1</label><caption><p>(a) In the side&#x02010;by&#x02010;side (SBS) deployment method, two self&#x02010;expanding metallic stents (SEMSs) were placed in parallel in the common bile duct after inserting two guidewires. (b) In the stent&#x02010;in&#x02010;stent (SIS) deployment method, the second guidewire was inserted through the mesh of the first SEMS, resulting in the overlapping of the two SEMSs in the common bile duct.</p></caption><graphic xlink:href="DEO2-5-e70075-g004" position="anchor" id="jats-graphic-1"/></fig></sec><sec id="deo270075-sec-0100"><title>Chemotherapy</title><p>The chemotherapy regimens used for first&#x02010;line therapy varied and included gemcitabine alone (GEM), gemcitabine plus cisplatin (GC), GC plus S&#x02010;1 (GCS), and GC plus an investigational drug. All patients received at least one cycle of chemotherapy and none received external radiation therapy. Oncologists selected regimens based on patient condition and complication risk.</p></sec><sec id="deo270075-sec-0110"><title>Follow&#x02010;up and definitions of events</title><p>Data on recurrent biliary obstruction (RBO), clinical success, and adverse events (AEs) were defined according to the TOKYO criteria.<xref rid="deo270075-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Clinical success was defined as serum bilirubin level normalization or a &#x02265;50% decrease within 14 days, or&#x000a0;&#x0003c;75% of the pretreatment value within 1 month.<xref rid="deo270075-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="deo270075-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Early and late AEs were defined as any stent or procedure&#x02010;related AEs developing within and after 30 days of SEMS placement, respectively. RBO was defined as stent occlusion or migration and time&#x02010;to&#x02010;recurrent biliary obstruction (TRBO) as the length of time between the SEMS placement and development of RBO. Censoring in TRBO was defined as death without stent occlusion or termination of follow&#x02010;up. Stent occlusion was defined as recurrence of jaundice and cholestasis and/or evidence of biliary dilation on imaging studies, necessitating biliary re&#x02010;intervention. Time&#x02010;to&#x02010;treatment failure (TTF) was defined as the period from the start date of chemotherapy to the final administration date of first&#x02010;line chemotherapy. Overall survival (OS) is defined as the length of time from the start of treatment until death from any cause. Censoring in OS was defined as the end of follow&#x02010;up without observed death.</p></sec><sec id="deo270075-sec-0120"><title>Statistical analysis</title><p>Categorical variables were compared by the chi&#x02010;square or Fisher's exact test, and continuous variables by the Student <italic toggle="yes">t</italic>&#x02010;test or Wilcoxon rank&#x02010;sum test. A Cox proportional hazards model was used to estimate the hazard ratios and 95% confidence intervals (95% CIs). A <italic toggle="yes">p</italic>&#x02010;value&#x000a0;&#x0003c;0.05 in a two&#x02010;sided test was considered as denoting statistical significance. TRBO was estimated using the Kaplan&#x02013;Meier method and compared between groups using the log&#x02010;rank test. Deaths without RBO were treated as censored at the time of death. R software, version 4.1.3 was used for all the statistical analyses.</p></sec></sec><sec id="deo270075-sec-0130"><title>RESULTS</title><p>A review of our database revealed that a total of 174 patients had undergone hilar multi&#x02010;stenting. We extracted 62 patients who had undergone stent placement prior to the initiation or second cycle of first&#x02010;line chemotherapy; of these, the stent deployment was performed by the SBS technique in 40 patients, and by the SIS technique in 22 patients. The median follow&#x02010;up period was 287.5 days. A flowchart of patient recruitment for the present study is shown in Figure&#x000a0;<xref rid="deo270075-fig-0002" ref-type="fig">2</xref>. The clinicopathological characteristics of the patients are shown in Table&#x000a0;<xref rid="deo270075-tbl-0001" ref-type="table">1</xref>. While there were fewer patients with metastatic disease in the SBS group than in the SIS group (<italic toggle="yes">p =</italic>&#x000a0;0.018), there was no statistically significant difference in the sex, age, performance status, cancer type, Bismuth classification,<xref rid="deo270075-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> chemotherapeutic regimens used, or the number of patients who had undergone endoscopic sphincterotomy between the two groups.</p><fig position="float" fig-type="FIGURE" id="deo270075-fig-0002"><label>FIGURE 2</label><caption><p>A flowchart showing patient selection. A review of our database identified 174 patients who underwent hilar multi&#x02010;stenting. We included 62 patients who had stent placement prior to the initiation or second cycle of first&#x02010;line chemotherapy. Among these 40 patients received stent placement using the side&#x02010;by&#x02010;side technique, while 22 patients received the stent&#x02010;in&#x02010;stent technique.</p></caption><graphic xlink:href="DEO2-5-e70075-g002" position="anchor" id="jats-graphic-3"/></fig><table-wrap position="float" id="deo270075-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Comparison of the clinical characteristics between the side&#x02010;by&#x02010;side and stent&#x02010;in&#x02010;stent groups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">SBS</th><th align="left" rowspan="1" colspan="1">SIS</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number of patients, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">40 (65)</td><td align="char" rowspan="1" colspan="1">22 (35)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Sex, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.35</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Male</td><td align="char" rowspan="1" colspan="1">30 (75)</td><td align="char" rowspan="1" colspan="1">14 (64)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Female</td><td align="char" rowspan="1" colspan="1">10 (25)</td><td align="char" rowspan="1" colspan="1">8 (36)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.67</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Median (range)</td><td align="char" rowspan="1" colspan="1">70.5 (50&#x02013;88)</td><td align="char" rowspan="1" colspan="1">72.5 (34&#x02013;86)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="3" align="left" rowspan="1">Performance status, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">0.66</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">0</td><td align="char" rowspan="1" colspan="1">39 (98)</td><td align="char" rowspan="1" colspan="1">21 (95)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">1/2</td><td align="char" rowspan="1" colspan="1">1 (3)</td><td align="char" rowspan="1" colspan="1">1 (5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cancer type, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.35</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">PHC</td><td align="char" rowspan="1" colspan="1">12 (30)</td><td align="char" rowspan="1" colspan="1">11 (50)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">DCC</td><td align="char" rowspan="1" colspan="1">6 (15)</td><td align="char" rowspan="1" colspan="1">1 (5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">ICC</td><td align="char" rowspan="1" colspan="1">5 (13)</td><td align="char" rowspan="1" colspan="1">1 (5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">GBC</td><td align="char" rowspan="1" colspan="1">17 (43)</td><td align="char" rowspan="1" colspan="1">9 (41)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.018</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Locally advanced</td><td align="char" rowspan="1" colspan="1">27 (68)</td><td align="char" rowspan="1" colspan="1">8 (36)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Metastatic</td><td align="char" rowspan="1" colspan="1">13 (33)</td><td align="char" rowspan="1" colspan="1">14 (64)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Bismuth type, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.57</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">I</td><td align="char" rowspan="1" colspan="1">5 (13)</td><td align="char" rowspan="1" colspan="1">1 (5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">II</td><td align="char" rowspan="1" colspan="1">29 (73)</td><td align="char" rowspan="1" colspan="1">18 (82)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">III</td><td align="char" rowspan="1" colspan="1">6 (15)</td><td align="char" rowspan="1" colspan="1">3 (14)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="3" align="left" rowspan="1">Chemotherapeutic regimen, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">GC</td><td align="char" rowspan="1" colspan="1">23 (58)</td><td align="char" rowspan="1" colspan="1">6 (27)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">GC+ ID</td><td align="char" rowspan="1" colspan="1">5 (13)</td><td align="char" rowspan="1" colspan="1">5 (23)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">GCS</td><td align="char" rowspan="1" colspan="1">11 (28)</td><td align="char" rowspan="1" colspan="1">10 (45)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">GEM</td><td align="char" rowspan="1" colspan="1">1 (3)</td><td align="char" rowspan="1" colspan="1">1 (5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Best response, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">CR</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">1 (5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">PR</td><td align="char" rowspan="1" colspan="1">3 (8)</td><td align="char" rowspan="1" colspan="1">2 (9)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">SD</td><td align="char" rowspan="1" colspan="1">29 (73)</td><td align="char" rowspan="1" colspan="1">13 (59)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">PD</td><td align="char" rowspan="1" colspan="1">8 (20)</td><td align="char" rowspan="1" colspan="1">5 (23)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">NE</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">1 (5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Objective response rate (%)</td><td align="char" rowspan="1" colspan="1">7.5</td><td align="char" rowspan="1" colspan="1">13.6</td><td align="left" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" rowspan="1" colspan="1">Disease control rate (%)</td><td align="char" rowspan="1" colspan="1">80.0</td><td align="char" rowspan="1" colspan="1">72.7</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" colspan="4" rowspan="1">Timing of chemotherapy initiation, <italic toggle="yes">n</italic> (%)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Post stent placement</td><td align="char" rowspan="1" colspan="1">33 (83)</td><td align="char" rowspan="1" colspan="1">22 (100)</td><td align="left" rowspan="1" colspan="1">0.10</td></tr><tr><td colspan="4" align="left" rowspan="1">History of endoscopic sphincterotomy, <italic toggle="yes">n</italic> (%)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Present</td><td align="char" rowspan="1" colspan="1">31 (78)</td><td align="char" rowspan="1" colspan="1">13 (59)</td><td align="left" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">Follow&#x02010;up period (days)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Median (range)</td><td align="char" rowspan="1" colspan="1">275 (59&#x02013;1062)</td><td align="char" rowspan="1" colspan="1">296 (83&#x02013;955)</td><td align="left" rowspan="1" colspan="1">0.64</td></tr></tbody></table><table-wrap-foot><fn id="deo270075-tbl1-note-0001"><p>Abbreviations: DCC, distal cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma; GBC, gallbladder carcinoma; GC, gemcitabine plus cisplatin; GCS, gemcitabine, cisplatin plus S&#x02010;1; GEM, gemcitabine; ID, investigational drug; NE, not evaluable; PHC, perihilar cholangiocarcinoma; SBS, side&#x02010;by&#x02010;side; SIS, stent&#x02010;in&#x02010;stent.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>The details of the stent placement procedures are shown in Table&#x000a0;<xref rid="deo270075-tbl-0002" ref-type="table">2</xref>. As for the endoscopists who performed the procedures, 17 (43%) and eight patients (36%) were treated by expert endoscopists, and 23 (58%) and 14 patients (64%) were treated by trainee endoscopists in the SBS and SIS groups, respectively, with no significant differences between the two groups (<italic toggle="yes">p =</italic>&#x000a0;0.35). For SBS deployment, the uncovered SEMSs were placed across the papilla in 37 patients (92.5%) and above the papilla in three patients (7.5%). For SIS deployment, the uncovered SEMSs were placed above the papilla in 21 patients (95.5%), and across the papilla in one patient (5.5%). Therefore, the stents were more frequently placed across the papilla in the SBS group and above the papilla in the SIS group (<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.01). Clinical success was achieved in all (100%) patients of the SBS group and all (100%) patients of the SIS group.</p><table-wrap position="float" id="deo270075-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Details of the biliary stenting procedure.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">SBS</th><th align="left" rowspan="1" colspan="1">SIS</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Endoscopists, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Trainees</td><td align="char" rowspan="1" colspan="1">23 (58)</td><td align="char" rowspan="1" colspan="1">14 (64)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Experts</td><td align="char" rowspan="1" colspan="1">17 (43)</td><td align="char" rowspan="1" colspan="1">8 (36)</td><td align="char" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of inserted stents, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Two</td><td align="char" rowspan="1" colspan="1">37 (93)</td><td align="char" rowspan="1" colspan="1">22 (100)</td><td align="char" rowspan="1" colspan="1">0.19</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Three</td><td align="char" rowspan="1" colspan="1">3 (8)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stent position, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Above the papilla</td><td align="char" rowspan="1" colspan="1">3 (8)</td><td align="char" rowspan="1" colspan="1">21 (95)</td><td align="char" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Across the papilla</td><td align="char" rowspan="1" colspan="1">37 (93)</td><td align="char" rowspan="1" colspan="1">1 (5)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Clinical success, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">40 (100)</td><td align="char" rowspan="1" colspan="1">22 (100)</td><td align="char" rowspan="1" colspan="1">1.00</td></tr></tbody></table><table-wrap-foot><fn id="deo270075-tbl2-note-0001"><p>Abbreviations: SBS, side&#x02010;by&#x02010;side; SIS, stent&#x02010;in&#x02010;stent.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Early and late AEs in the SBS and SIS groups are shown in Table&#x000a0;<xref rid="deo270075-tbl-0003" ref-type="table">3</xref>. Early AEs occurred in 11 (28%) patients of the SBS group and two (9%) patients of the SIS group (<italic toggle="yes">p =</italic>&#x000a0;0.09), with a tendency toward a higher frequency of early AEs in the SBS group as compared with the SIS group. The main early AEs in the SBS group and SIS group were pancreatitis in eight patients (20%) and two patients (9%), cholecystitis in one patient (3%) and 0 patient (0%), and cholangitis in three patients (8%) and 0 patients (0%), respectively. Late AEs occurred in 10 (25%) patients of the SBS group and three (14%) patients of the SIS group, and included liver abscess, hemobilia, cholangitis, and biloma. Liver abscess occurred in five (13%) and two patients (9%), hemobilia in two (5&#x0ff05;) and 0 patients (0%), cholangitis in three (8%) and 0 patients (0%), and biloma in 0 (0%) and one patient (5%) of the SBS and SIS groups, respectively.</p><table-wrap position="float" id="deo270075-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Early and late adverse events of stent deployment by the side&#x02010;by&#x02010;side and stent&#x02010;in&#x02010;stent techniques.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">SBS</th><th align="left" rowspan="1" colspan="1">SIS</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Early adverse events, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">11 (28)</td><td align="char" rowspan="1" colspan="1">2 (9)</td><td rowspan="4" align="left" colspan="1">0.09</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Pancreatitis, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">8 (20)</td><td align="char" rowspan="1" colspan="1">2 (9)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Cholecystitis, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">1 (3)</td><td align="char" rowspan="1" colspan="1">0 (0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Cholangitis, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">3 (8)</td><td align="char" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Late adverse events</td><td align="char" rowspan="1" colspan="1">10 (25)</td><td align="char" rowspan="1" colspan="1">3 (14)</td><td rowspan="5" align="left" colspan="1">0.27</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Liver abscess, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">5 (13)</td><td align="char" rowspan="1" colspan="1">2 (9)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Hemobilia, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">2 (5)</td><td align="char" rowspan="1" colspan="1">0 (0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Cholangitis, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">3 (8)</td><td align="char" rowspan="1" colspan="1">0 (0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Biloma, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">1 (5)</td></tr></tbody></table><table-wrap-foot><fn id="deo270075-tbl3-note-0001"><p>Abbreviations: SBS, side&#x02010;by&#x02010;side; SIS, stent&#x02010;in&#x02010;stent.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>The clinical outcomes in the SBS and SIS groups are shown in Table&#x000a0;<xref rid="deo270075-tbl-0004" ref-type="table">4</xref>. The RBO rates tended to be higher in the SBS group (75%) than in the SIS group (50%; <italic toggle="yes">p =</italic>&#x000a0;0.056). In the SBS group, there were three cases in which the stents were placed above the papilla; two of these cases developed RBO. The major causes of RBO were tumor ingrowth (38%) and sludge (33&#x0ff05;) in the SBS group, and tumor ingrowth (32%) in the SIS group. The cumulative TRBOs are shown in Figure&#x000a0;<xref rid="deo270075-fig-0003" ref-type="fig">3</xref>. The median TRBO was shorter in the SBS group (median: 147 days) as compared with the SIS group (median: 252 days; hazard ratio [HR] 2.06; 95% CI 1.03&#x02013;4.13; <italic toggle="yes">p =</italic>&#x000a0;0.029). Censoring in TRBO occurred in 22 of 62 patients (35%), and RBO occurred in 40 of 62 patients (65%). There was no significant difference in the rate of conversion to percutaneous transhepatic biliary drainage after RBO (10% in the SBS group and 18% in the SIS group; <italic toggle="yes">p =</italic>&#x000a0;0.36), rate of conversion to endoscopic ultrasound&#x02010;guided biliary drainage after RBO (13% in the SBS group and 0% in the SIS group; <italic toggle="yes">p =</italic>&#x000a0;0.087), or cumulative TRBO after re&#x02010;intervention (101 days in the SBS group and 81 days in the SIS group; HR 1.64; 95% CI 0.62&#x02013;4.3; <italic toggle="yes">p =</italic>&#x000a0;0.48) between the two groups. The total number of sessions of re&#x02010;intervention during the follow&#x02010;up was higher in the SBS group (median: 2) as compared with the SIS group (median: 1; <italic toggle="yes">p =</italic>&#x000a0;0.006).</p><table-wrap position="float" id="deo270075-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Clinical outcomes of patients undergoing stent deployment by the side&#x02010;by&#x02010;side and stent&#x02010;in&#x02010;stent techniques.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">SBS</th><th align="left" rowspan="1" colspan="1">SIS</th><th align="left" rowspan="1" colspan="1">Hazard ratio (95% CI)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">RBO rates, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">30 (75)</td><td align="char" rowspan="1" colspan="1">11(50)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.056</td></tr><tr><td align="left" rowspan="1" colspan="1">RBO, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Sludge</td><td align="char" rowspan="1" colspan="1">13 (33)</td><td align="char" rowspan="1" colspan="1">4 (18)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.78</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Ingrowth</td><td align="char" rowspan="1" colspan="1">15 (38)</td><td align="char" rowspan="1" colspan="1">7 (32)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Overgrowth</td><td align="char" rowspan="1" colspan="1">1 (3)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Migration</td><td align="char" rowspan="1" colspan="1">1 (3)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cumulative TRBO (days)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Median (95% CI)</td><td align="char" rowspan="1" colspan="1">147 (99&#x02013;193)</td><td align="char" rowspan="1" colspan="1">252 (132&#x02013;544)</td><td align="left" rowspan="1" colspan="1">2.06 (1.03&#x02013;4.13)</td><td align="left" rowspan="1" colspan="1">0.029</td></tr><tr><td align="left" rowspan="1" colspan="1">Total number of re&#x02010;intervention sessions during follow&#x02010;up</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Median (Range)</td><td align="char" rowspan="1" colspan="1">2 (0&#x02010;12)</td><td align="char" rowspan="1" colspan="1">1 (0&#x02010;6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">Conversion to PTBD after RBO, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">4 (10)</td><td align="char" rowspan="1" colspan="1">4 (18)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">Conversion to EUS&#x02010;BD after RBO, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">5 (13)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.087</td></tr><tr><td align="left" rowspan="1" colspan="1">Cumulative TRBO after re&#x02010;intervention (days)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Median (95% CI)</td><td align="char" rowspan="1" colspan="1">101 (21&#x02013;872)</td><td align="char" rowspan="1" colspan="1">81 (10&#x02013;615)</td><td align="left" rowspan="1" colspan="1">1.64 (0.62&#x02013;4.3)</td><td align="left" rowspan="1" colspan="1">0.48</td></tr></tbody></table><table-wrap-foot><fn id="deo270075-tbl4-note-0001"><p>Abbreviations: CI, confidence interval; EUS&#x02010;BD, endoscopic ultrasound&#x02010;guided biliary drainage; PTBD, percutaneous transhepatic biliary drainage; RBO, recurrent biliary obstruction; SBS, side&#x02010;by&#x02010;side; SIS, stent&#x02010;in&#x02010;stent; TRBO, time&#x02010;to&#x02010;recurrent biliary obstruction.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><fig position="float" fig-type="FIGURE" id="deo270075-fig-0003"><label>FIGURE 3</label><caption><p>Kaplan&#x02013;Meier curves for time&#x02010;to&#x02010;recurrent biliary obstruction. The median time&#x02010;to&#x02010;recurrent biliary obstruction (TRBO) was shorter in the side&#x02010;by&#x02010;side (SBS) group compared to the stent&#x02010;in&#x02010;stent (SIS) group, with medians of 147 days and 252 days, respectively (hazard ratio 2.06; 95% confidence interval 1.03&#x02013;4.13; <italic toggle="yes">p</italic> =&#x000a0;0.029).</p></caption><graphic xlink:href="DEO2-5-e70075-g003" position="anchor" id="jats-graphic-5"/></fig><p>We also assessed the TTF and rate of treatment interruption due to RBO during first&#x02010;line chemotherapy, and the results are shown in Table&#x000a0;<xref rid="deo270075-tbl-0005" ref-type="table">5</xref>. TTF of first&#x02010;line chemotherapy was 322 days in the SBS group and 475 days in the SIS group (HR 1.09; 95% CI 0.6&#x02013;1.96; <italic toggle="yes">p =</italic>&#x000a0;0.31). During first&#x02010;line chemotherapy, 63% of patients in the SBS group and 45% of patients in the SIS group needed interruption of chemotherapy due to RBO (<italic toggle="yes">p =</italic>&#x000a0;0.285). The OS are shown in Table&#x000a0;<xref rid="deo270075-tbl-0005" ref-type="table">5</xref> and Figure&#x000a0;<xref rid="deo270075-fig-0004" ref-type="fig">4</xref>. The median OS was 480 days in the SBS group and 563 days in the SIS group (HR 1.20; 95% CI 0.53&#x02013;2.71; <italic toggle="yes">p =</italic>&#x000a0;0.92), with no significant difference between the two groups.</p><table-wrap position="float" id="deo270075-tbl-0005" content-type="TABLE"><label>TABLE 5</label><caption><p>Clinical outcomes of patients treated by systemic chemotherapy.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">SBS</th><th align="left" rowspan="1" colspan="1">SIS</th><th align="left" rowspan="1" colspan="1">Hazard ratio (95% CI)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Time&#x02010;to&#x02010;treatment failure</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median (95% CI)</td><td align="left" rowspan="1" colspan="1">322 (126&#x02013;422)</td><td align="left" rowspan="1" colspan="1">475 (161&#x02013;NA)</td><td align="left" rowspan="1" colspan="1">1.088 (0.6&#x02013;1.96)</td><td align="left" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment interruption due to RBO, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">25 (63)</td><td align="left" rowspan="1" colspan="1">12 (45)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.285</td></tr><tr><td align="left" rowspan="1" colspan="1">Overall survival (days)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Median (95% CI)</td><td align="left" rowspan="1" colspan="1">480 (271&#x02013;620)</td><td align="left" rowspan="1" colspan="1">563 (282&#x02010;NA)</td><td align="left" rowspan="1" colspan="1">1.196 (0.53&#x02013;2.71)</td><td align="left" rowspan="1" colspan="1">0.92</td></tr></tbody></table><table-wrap-foot><fn id="deo270075-tbl5-note-0001"><p>Abbreviations: CI, confidence interval; NA, not available; RBO, recurrent biliary obstruction; SBS, side&#x02010;by&#x02010;side; SIS, stent&#x02010;in&#x02010;stent.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><fig position="float" fig-type="FIGURE" id="deo270075-fig-0004"><label>FIGURE 4</label><caption><p>Kaplan&#x02013;Meier curves for overall survival (OS). The median OS was 480 days in the side&#x02010;by&#x02010;side (SBS) group and 563 days in the stent&#x02010;in&#x02010;stent (SIS) group, with no significant difference between the two groups (hazard ratio 1.20; 95% confidence interval 0.53&#x02013;2.71; <italic toggle="yes">p</italic> =&#x000a0;0.92).</p></caption><graphic xlink:href="DEO2-5-e70075-g001" position="anchor" id="jats-graphic-7"/></fig><p>We performed multivariate analysis to compare the TRBO between the groups that received stent deployment by the SBS and SIS methods, by controlling for confounding factors and using stent position, timing to chemotherapy initiation, clinical disease stage, and stenting technique as independent variables, and the results are shown in Table <xref rid="deo270075-supinfo-0001" ref-type="">S1</xref>. None of the factors were identified as showing any statistically significant associations.</p></sec><sec id="deo270075-sec-0140"><title>DISCUSSION</title><p>We compared the duration of stent patency between unresectable BTC patients with hilar MBO who underwent stent deployment by the SBS and SIS techniques during systemic chemotherapy; the results revealed that the duration of stent patency was significantly shorter in the SBS group than in the SIS group. Previously, SEMSs in the SBS group were frequently placed across the papilla due to kinking risk and re&#x02010;intervention difficulty,<xref rid="deo270075-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> leading to more duodenal reflux and sludge retention. On the other hand, the SEMS were more often implanted above the papilla in the SIS group; as the SEMSs were overlapping in the common bile duct and re&#x02010;intervention was not difficult even when the stents were placed above the papilla. Less exposure of the stent to the duodenal lumen likely reduces the risk of obstruction from food residue and sludge retention, contributing to a longer duration of stent patency. This might contribute to the longer&#x02010;term stent patency. Furthermore, in the SIS group, the stents were overlapping in the common bile duct, therefore the stents could be placed in a natural manner with no overexpansion, which could have contributed to the longer stent patency and lower need for re&#x02010;intervention compared to the SBS group. Recent meta&#x02010;analyses reported a shorter duration of patency and higher re&#x02010;intervention rates for stent deployment by the SBS method as compared with the SIS method, although the superiority of either technique remains under debate.<xref rid="deo270075-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> The rate of early AEs rate tended to be higher in the SBS group, although there was no significant difference in the rate of late AEs between the two groups. SBS stent placement involves parallel bile duct stenting, which leads to early complications due to overexpansion of the bile duct. This finding of ours was also consistent with previous reports.<xref rid="deo270075-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="deo270075-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p><p>However, this study included a mix of patients with a variety of cancer types who had and had not received chemotherapy, which made it difficult to determine the exact duration of stent patency in chemotherapy&#x02010;eligible biliary tract cancer patients; it was also not possible to determine the effect of the stent deployment technique on the possibility of continuation or need for discontinuation of chemotherapy.</p><p>We examined the effect of first&#x02010;line chemotherapy according to the stenting method used. Treatment interruption due to RBO was more frequent and the TTF was slightly shorter in the SBS group than in the SIS group. These findings suggest that systemic chemotherapy could be continued for longer without interruption by RBO in the SIS group. Although there are no studies that examined the effect of stenting format on chemotherapy in biliary tract cancer during chemotherapy, there are some studies that compared the duration of patency of plastic and covered metal stents in pancreatic cancer during chemotherapy and reported that the metal stents had less occlusion and longer patency.<xref rid="deo270075-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="deo270075-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> The selection of appropriate stenting is considered important for the long&#x02010;term continuation of chemotherapy.</p><p>RBO occurring in the short term might necessitate interruption or discontinuation of chemotherapy. Longer patency durations of stents could also improve the patient's quality of life by reducing the number of re&#x02010;interventional procedures and hospitalizations required due to RBO. Until now, there have been few studies on the stent patency duration in unresectable BTC patients receiving systemic chemotherapy, and prior studies on the subject were limited by the varied cancer types and chemotherapy status of the patients.<xref rid="deo270075-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="deo270075-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="deo270075-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="deo270075-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> To address these issues, this study was limited to patients with biliary tract cancer before or immediately after the introduction of first&#x02010;line chemotherapy. The results of this study revealed that in patients undergoing systemic chemotherapy for unresectable BTC, stent insertion by the SIS technique yielded longer stent patency as compared with stent insertion by the SBS technique, consequently allowing for long&#x02010;term continuation of systemic chemotherapy without interruption or discontinuation due to the development of RBO.</p><p>Our study had limitations. First, it was a single&#x02010;center retrospective study. Because this was not a randomized controlled trial and was conducted on a rather small number of cases, the possibility of unintentional selection bias of patients cannot be fully excluded. Secondly, this study included patients who underwent multi&#x02010;stenting before the first or second cycle of first&#x02010;line chemotherapy to ensure the number of cases, it would be preferable to focus on patients in which the stent was inserted before the start of chemotherapy to examine TRBO more accurately. Thirdly, the chemotherapy regimens were varied, which may prevent an accurate comparison of the results. In addition, treatment with GC + durvalumab and GC + pembrolizumab, which are standard regimens for unresectable BTC at present, had not yet been approved during this study period in Japan. Therefore, these treatments were not included in our analysis. Nevertheless, our findings can be examined in future randomized controlled trials with uniformity regarding the type of chemotherapy in patients who had a stent inserted before chemotherapy, which will provide more reproducible results on the duration of stent patency during chemotherapy. Fourthly, we often placed the SEMS across the papilla in the SBS group; the location of the distal end of the stent is undoubtedly an important factor with respect to the TRBO, and multivariate analysis performed with the stent position included as a variable did not show any advantage for SIS. However, the deployment method could vary among institutions, potentially limiting its generalizability.</p><p>In conclusion, in patients with unresectable BTC receiving systemic chemotherapy, the stent patency duration was significantly shorter in patients who underwent stent insertion by the SBS technique rather than by the SIS technique. Furthermore, stent placement by the SIS technique was associated with a reduced need for re&#x02010;intervention and chemotherapy interruptions and was preferred over stent placement by the SBS technique.</p></sec><sec sec-type="COI-statement" id="deo270075-sec-0150"><title>CONFLICT OF INTEREST STATEMENT</title><p>Masafumi Ikeda has received research funding (institution) from AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Chugai, Chiome Bioscience, Delta&#x02010;Fly Pharma, Eisai, Eli Lilly Japan, Invitae, MSD, J&#x02010;Pharma, Merck biopharma, Merus N.V., Novartis, Nihon Servier, Ono, Pfizer, and Syneos Health, consulted for AstraZeneca, Chugai, MSD, Nihon Servier, and Novartis, and received speaker honoraria from AbbVie, AstraZeneca, Chugai, Eisai, Eli Lilly Japan, Fujifilm Toyama Chemical, Guardant Health Japan, Incyte Biosciences Japan, MSD, Nihon Servier, Novartis, Nippon Kayaku, Ono, Taisho Pharmaceutical, Teijin, Takeda, Taiho, and Yakult. Shuichi Mitsunaga has received research funding from Chugai, Astellas, Toray, Ajinomoto, and Pfizer, and received speaker honoraria from Ono, Toray, and Otsuka. HI has received research funding from Ono, and Novartis, consulted for Nihon Servier, and Kaneka Medix, and received speaker honoraria from Yakult, AstraZeneca, Nihon Servier, Kaneka Medix, Boston Scientific, and SB&#x02010;Kawasumi Laboratories. The other authors declare no conflict of interest.</p></sec><sec id="deo270075-sec-0160"><title>ETHICS STATEMENT</title><p>The study protocol was approved by the Institutional Review Board of the National Cancer Center.</p></sec><sec id="deo270075-sec-0170"><title>PATIENT CONSENT STATEMENT</title><p>N/A.</p></sec><sec id="deo270075-sec-0180"><title>CLINICAL TRIAL REGISTRATION</title><p>N/A.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="deo270075-supinfo-0001" position="float" content-type="local-data"/><supplementary-material id="deo270075-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>TABLE S1</bold> Multivariate analysis to identify factors influencing the TRBO.</p></caption><media xlink:href="DEO2-5-e70075-s001.docx"/></supplementary-material></sec></body><back><ref-list id="deo270075-bibl-0001"><title>REFERENCES</title><ref id="deo270075-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="deo270075-cite-0001">
<string-name>
<surname>Takahashi</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Fukasawa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sato</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Biliary drainage strategy of unresectable malignant hilar strictures by computed tomography volumetry</article-title>. <source>World J Gastroenterol</source>
<year>2015</year>; <volume>21</volume>: <fpage>4946</fpage>&#x02013;<lpage>4953</lpage>.<pub-id pub-id-type="pmid">25945008</pub-id>
</mixed-citation></ref><ref id="deo270075-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="deo270075-cite-0002">
<string-name>
<surname>Dumas</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Demuth</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Buckley</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Endoscopic bilateral metal stent placement for malignant hilar stenoses: Identification of optimal technique</article-title>. <source>Gastrointest Endosc</source>
<year>2000</year>; <volume>51</volume>: <fpage>334</fpage>&#x02013;<lpage>338</lpage>.<pub-id pub-id-type="pmid">10699784</pub-id>
</mixed-citation></ref><ref id="deo270075-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="deo270075-cite-0003">
<string-name>
<surname>Rerknimitr</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Angsuwatcharakon</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ratanachu&#x02010;ek</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Asia&#x02013;Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma</article-title>. <source>J Gastroenterol Hepatol</source>
<year>2013</year>; <volume>28</volume>: <fpage>593</fpage>&#x02013;<lpage>607</lpage>.<pub-id pub-id-type="pmid">23350673</pub-id>
</mixed-citation></ref><ref id="deo270075-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo270075-cite-0004">
<string-name>
<surname>Naitoh</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Ohara</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nakazawa</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Unilateral versus bilateral endoscopic metal stenting for malignant hilar biliary obstruction</article-title>. <source>J Gastroenterol Hepatol</source>
<year>2009</year>; <volume>24</volume>: <fpage>552</fpage>&#x02013;<lpage>557</lpage>.<pub-id pub-id-type="pmid">19220678</pub-id>
</mixed-citation></ref><ref id="deo270075-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo270075-cite-0005">
<string-name>
<surname>Kogure</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Isayama</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nakai</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>High single&#x02010;session success rate of endoscopic bilateral stent&#x02010;in&#x02010;stent placement with modified large cell Niti&#x02010;S stents for malignant hilar biliary obstruction</article-title>. <source>Dig Endosc</source>
<year>2014</year>; <volume>26</volume>: <fpage>93</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="pmid">23517109</pub-id>
</mixed-citation></ref><ref id="deo270075-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo270075-cite-0006">
<string-name>
<surname>Lee</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>KH</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Small cell&#x02010; versus large cell&#x02010;sized metal stent in endoscopic bilateral stent&#x02010;in&#x02010;stent placement for malignant hilar biliary obstruction</article-title>. <source>Dig Endosc</source>
<year>2015</year>; <volume>27</volume>: <fpage>692</fpage>&#x02013;<lpage>699</lpage>.<pub-id pub-id-type="pmid">25708157</pub-id>
</mixed-citation></ref><ref id="deo270075-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="deo270075-cite-0007">
<string-name>
<surname>Kato</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yabe</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Muro</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Endoscopic transpapillary biliary drainage for malignant hilar biliary obstruction</article-title>. <source>Shokaki Naishikyo</source>
<year>2018</year>; <volume>30</volume>: <fpage>1524</fpage>&#x02013;<lpage>1529</lpage>. (In Japanese)</mixed-citation></ref><ref id="deo270075-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="deo270075-cite-0008">
<string-name>
<surname>Kim</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>YH</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>A comparison of bilateral stenting methods for malignant hilar biliary obstruction</article-title>. <source>Hepatogastroenterology</source>
<year>2012</year>; <volume>59</volume>: <fpage>341</fpage>&#x02013;<lpage>346</lpage>.<pub-id pub-id-type="pmid">22353496</pub-id>
</mixed-citation></ref><ref id="deo270075-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="deo270075-cite-0009">
<string-name>
<surname>Ishigaki</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hamada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nakai</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Retrospective comparative study of side&#x02010;by&#x02010;side and stent&#x02010;in&#x02010;stent metal stent placement for hilar malignant biliary obstruction</article-title>. <source>Dig Dis Sci</source>
<year>2020</year>; <volume>65</volume>: <fpage>3710</fpage>&#x02013;<lpage>3718</lpage>.<pub-id pub-id-type="pmid">32107675</pub-id>
</mixed-citation></ref><ref id="deo270075-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="deo270075-cite-0010">
<string-name>
<surname>Naitoh</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Hayashi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nakazawa</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Side&#x02010;by&#x02010;side versus stent&#x02010;in&#x02010;stent deployment in bilateral endoscopic metal stenting for malignant hilar biliary obstruction</article-title>. <source>Dig Dis Sci</source>
<year>2012</year>; <volume>57</volume>: <fpage>3279</fpage>&#x02013;<lpage>3285</lpage>.<pub-id pub-id-type="pmid">22732832</pub-id>
</mixed-citation></ref><ref id="deo270075-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="deo270075-cite-0011">
<string-name>
<surname>de Souza</surname>
<given-names>GMV</given-names>
</string-name>, <string-name>
<surname>Ribeiro</surname>
<given-names>IB</given-names>
</string-name>, <string-name>
<surname>Funari</surname>
<given-names>MP</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Endoscopic retrograde cholangiopancreatography drainage for palliation of malignant hilar biliary obstruction &#x02010; Stent&#x02010;in&#x02010;stent or side&#x02010;by&#x02010;side? A systematic review and meta&#x02010;analysis</article-title>. <source>World J Hepatol</source>
<year>2021</year>; <volume>13</volume>: <fpage>595</fpage>&#x02013;<lpage>610</lpage>.<pub-id pub-id-type="pmid">34131473</pub-id>
</mixed-citation></ref><ref id="deo270075-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="deo270075-cite-0012">
<string-name>
<surname>Isayama</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hamada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fujisawa</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>TOKYO criteria 2024 for the assessment of clinical outcomes of endoscopic biliary drainage</article-title>. <source>Dig Endosc</source>
<year>2024</year>; <volume>36</volume>: <fpage>1195</fpage>&#x02013;<lpage>1210</lpage>.<pub-id pub-id-type="pmid">38845085</pub-id>
</mixed-citation></ref><ref id="deo270075-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="deo270075-cite-0013">
<string-name>
<surname>Bismuth</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Castaing</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Traynor</surname>
<given-names>O</given-names>
</string-name>. <article-title>Resection or palliation: Priority of surgery in the treatment of hilar cancer</article-title>. <source>World J Surg</source>
<year>1988</year>; <volume>12</volume>: <fpage>39</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">2449769</pub-id>
</mixed-citation></ref><ref id="deo270075-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="deo270075-cite-0014">
<string-name>
<surname>Tamura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Itonaga</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ashida</surname>
<given-names>R</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Covered self&#x02010;expandable metal stents versus plastic stents for preoperative biliary drainage in patient receiving neo&#x02010;adjuvant chemotherapy for borderline resectable pancreatic cancer: Prospective randomized study</article-title>. <source>Dig Endosc</source>
<year>2021</year>; <volume>33</volume>: <fpage>1170</fpage>&#x02013;<lpage>1178</lpage>.<pub-id pub-id-type="pmid">33410564</pub-id>
</mixed-citation></ref><ref id="deo270075-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="deo270075-cite-0015">
<string-name>
<surname>Kuwatani</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hayashi</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Clinical outcomes of biliary drainage during a neoadjuvant therapy for pancreatic cancer: Metal versus plastic stents</article-title>. <source>Gut Liver</source>
<year>2020</year>; <volume>14</volume>: <fpage>269</fpage>&#x02013;<lpage>273</lpage>.<pub-id pub-id-type="pmid">31060118</pub-id>
</mixed-citation></ref></ref-list></back></article>